Oxcarbazepine

Drug Profile

Oxcarbazepine

Alternative Names: GP 47680; KIN-493; NPC 04; Oxacarbazepine; TRI 476; Trileptal

Latest Information Update: 03 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Novartis; Queen Mary University of London
  • Class Antiepileptic drugs; Dibenzazepines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Epilepsy
  • Phase II Multiple sclerosis
  • Discontinued Bipolar disorders; Diabetic neuropathies; Neurological disorders

Most Recent Events

  • 31 Jan 2018 Queen Mary University of London completes a phase II trial in Multiple sclerosis in United Kingdom (PO) (NCT02104661)
  • 04 Jul 2016 Registered for Epilepsy in Japan (PO)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top